B LA025 D E 2
OM ELS 8-22
R S 1 EUBRUSMay
V I S I T
WORLD’S CLINICAL LABORATORY NEWS LEADER
ISSN 1068-1760
I
N
Vol.42 No.2 • 5/2025
T
Test Replaces Biopsies in Fungal Infections
F
or individuals with weakened immune systems, common molds found in the environment—such as in the soil, on damp walls, or on forgotten fruits—can lead to severe infections deep within the body. In patients undergoing chemo-
Cont’d on page 4
E
R
N
A
T
I
DAILY CLINICAL LAB NEWS
®
O
Breakthrough Technique Identifies Bacterial Infections Within 3 Hours
R
apid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization (FISH) technique facilitates the swift detection and identification
of microbes by leveraging differences in their genomic sequences, without the need for time-consuming culturing or sequencing. However, the growing volume of microbial genomic data has made it increasingly difficult to design appropriate probes for microbial Cont’d on page 12
Blood Test Accurately Measures Alzheimer’s Disease Progression
A
novel blood test not only diagnoses Alzheimer’s Disease but also accurately indicates the stage of progression as well as help differentiate Alzheimer’s symptoms from those caused by other conditions.
N
A
L
Handheld TB Testing In Less Than an Hour
T
uberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to the high cost and limitations of testing in regions with a heavy disease burden. The World Health Organization reports that over 1 million children contract TB each year, with more Cont’d on page 10
Rapid Molecular Blood Screening for CVD Risk
L
ipoproteins play a crucial role in cardiovascular health, with their composition and concentration closely linked to the risk of cardiovascular disease (CVD). They are also associated with a range of other medical conditions, including diabetes and obesity. Current clinical methods for lipoprotein profiling mainly focus on a limited set of blood markers, primarily aimed at assessing
See article on page 6
Cont’d on page 2 V
I
S
I
LINKXPRESS COM
R E A D E R
Blood Test Improves Survival in Triple-Negative Breast Cancer
T
S E R V I C E
®
C
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information: Identify LinkXpress ® codes of 1 interest as you read magazine on LinkXpress.com 2 toClick reach reader service portal Mark code(s) of interest on 3 LinkXpress ® inquiry matrix
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
I
INSIDE
ancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer is discovered at more advanced stages. One of the challenges in treating breast cancer, particularly
LabMedica EXPO . 6-20
Cont’d on page 5
Events Calendar . . 22
Clinical News . . . . 2 -16
IFCC News . . . . 17-19
Industry News .. . . . 21
Post-Treatment Blood Test Guides Future Cancer Therapy Decisions
n the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after their treatment. This tool is a form of molecular residual disease
(MRD) detector, which helps monitor the cancer status of patients after they have completed their primary treatment. Researchers suggest that this tool could play a crucial role in guiding clinical decisions, including determining whether to restart or intensify treatment. Cont’d on page 10
PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<